These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20570038)

  • 1. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Markovic-Plese S
    Clin Neurol Neurosurg; 2010 Sep; 112(7):641-5. PubMed ID: 20570038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation.
    Zhang X; Jin J; Tang Y; Speer D; Sujkowska D; Markovic-Plese S
    J Immunol; 2009 Mar; 182(6):3928-36. PubMed ID: 19265172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
    Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
    J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis.
    Ramgolam VS; Markovic-Plese S
    Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):161-7. PubMed ID: 20384573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis.
    Zhang X; Tao Y; Troiani L; Markovic-Plese S
    J Immunol; 2011 Sep; 187(6):3431-7. PubMed ID: 21856936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties and origin of human Th17 cells.
    Romagnani S; Maggi E; Liotta F; Cosmi L; Annunziato F
    Mol Immunol; 2009 Nov; 47(1):3-7. PubMed ID: 19193443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis.
    Schwab N; Zozulya AL; Kieseier BC; Toyka KV; Wiendl H
    J Immunol; 2010 May; 184(9):5368-74. PubMed ID: 20357264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M; Lindberg R; Raulf F; Kuhle J; Hess C; Kappos L; Brinkmann V
    Neurology; 2010 Aug; 75(5):403-10. PubMed ID: 20592255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease.
    Brereton CF; Sutton CE; Lalor SJ; Lavelle EC; Mills KH
    J Immunol; 2009 Aug; 183(3):1715-23. PubMed ID: 19570828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T cells.
    Crome SQ; Wang AY; Kang CY; Levings MK
    Eur J Immunol; 2009 Jun; 39(6):1480-93. PubMed ID: 19449310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
    de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis.
    Mus AM; Cornelissen F; Asmawidjaja PS; van Hamburg JP; Boon L; Hendriks RW; Lubberts E
    Arthritis Rheum; 2010 Apr; 62(4):1043-50. PubMed ID: 20131264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.